BridgeBio Pharma, Inc. Receivables, Long-term Contracts or Programs
BridgeBio Pharma, Inc. (BBIO) had Receivables, Long-term Contracts or Programs of $478.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:ReceivablesLongTermContractsOrPrograms · last filed 2024-11-12
- 2024-09-30: Receivables, Long-term Contracts or Programs $478.00K.
- 2024-06-30: Receivables, Long-term Contracts or Programs $660.00K.
- 2024-03-31: Receivables, Long-term Contracts or Programs $235.49M.
- 2023-12-31: Receivables, Long-term Contracts or Programs $1.75M.
| Period end | Receivables, Long-term Contracts or Programs |
|---|---|
| 2024-09-30 | $478.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $660.00K 10-Q · filed 2024-08-01 |
| 2024-03-31 | $235.49M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.75M 10-Q · filed 2024-11-12 |
| 2023-09-30 | $5.17M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $8.61M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $10.76M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $17.08M 10-K · filed 2024-02-22 |
| 2022-09-30 | $24.58M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $22.82M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $10.98M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $19.75M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |